View in EDS HTML Full Text PDF Full Text

The STELLAR trial: a phase II/III randomized trial of high-dose, intermittent sunitinib in patients with recurrent glioblastoma.

Saved in:
Bibliographic Details
Title: The STELLAR trial: a phase II/III randomized trial of high-dose, intermittent sunitinib in patients with recurrent glioblastoma.
Authors: Janssen JBE; Department of Medical Oncology, Research Institute for Medical Innovation, Radboud University Medical Center, 6525 GA, Nijmegen, The Netherlands., Brahm CG; Department of Medical Oncology, Cancer Center Amsterdam, Vrije Universiteit Amsterdam, Amsterdam UMC, 1081 HV, Amsterdam, The Netherlands., Driessen CML; Department of Medical Oncology, Research Institute for Medical Innovation, Radboud University Medical Center, 6525 GA, Nijmegen, The Netherlands., Nuver J; Department of Medical Oncology, University Medical Center Groningen, University Groningen, 9713 GZ, Groningen, The Netherlands., Labots M; Department of Medical Oncology, Cancer Center Amsterdam, Vrije Universiteit Amsterdam, Amsterdam UMC, 1081 HV, Amsterdam, The Netherlands., Kouwenhoven MCM; Department of Neurology, Cancer Center Amsterdam, Vrije Universiteit Amsterdam, Amsterdam UMC, 1081 HV, Amsterdam, The Netherlands., Sanchez Aliaga E; Department of Radiology and Nuclear Medicine, Vrije Universiteit Amsterdam, Amsterdam UMC, 1081 HV, Amsterdam, The Netherlands., Enting RH; Department of Neurology, University Medical Center Groningen, University Groningen, 9713 GZ, Groningen, The Netherlands., de Groot JC; Department of Radiology, Medical Imaging Center, University Medical Center Groningen, University Groningen, 9713 GZ, Groningen, The Netherlands., Walenkamp AME; Department of Medical Oncology, University Medical Center Groningen, University Groningen, 9713 GZ, Groningen, The Netherlands., van Linde ME; Department of Medical Oncology, Cancer Center Amsterdam, Vrije Universiteit Amsterdam, Amsterdam UMC, 1081 HV, Amsterdam, The Netherlands., Verheul HMW; Department of Medical Oncology, Research Institute for Medical Innovation, Radboud University Medical Center, 6525 GA, Nijmegen, The Netherlands.; Department of Medical Oncology, Erasmus University Medical Center, Cancer Institute, 3015 GD, Rotterdam, The Netherlands.
Source: Brain communications [Brain Commun] 2024 Jul 30; Vol. 6 (4), pp. fcae241. Date of Electronic Publication: 2024 Jul 30 (Print Publication: 2024).
Publication Type: Clinical Trial; Journal Article
Journal Info: Publisher: Oxford University Press Country of Publication: England NLM ID: 101755125 Publication Model: eCollection Cited Medium: Internet ISSN: 2632-1297 (Electronic) Linking ISSN: 26321297 NLM ISO Abbreviation: Brain Commun Subsets: PubMed not MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 39114330
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: The STELLAR trial: a phase II/III randomized trial of high-dose, intermittent sunitinib in patients with recurrent glioblastoma.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Janssen+JBE%22">Janssen JBE</searchLink>; Department of Medical Oncology, Research Institute for Medical Innovation, Radboud University Medical Center, 6525 GA, Nijmegen, The Netherlands.<br /><searchLink fieldCode="AU" term="%22Brahm+CG%22">Brahm CG</searchLink>; Department of Medical Oncology, Cancer Center Amsterdam, Vrije Universiteit Amsterdam, Amsterdam UMC, 1081 HV, Amsterdam, The Netherlands.<br /><searchLink fieldCode="AU" term="%22Driessen+CML%22">Driessen CML</searchLink>; Department of Medical Oncology, Research Institute for Medical Innovation, Radboud University Medical Center, 6525 GA, Nijmegen, The Netherlands.<br /><searchLink fieldCode="AU" term="%22Nuver+J%22">Nuver J</searchLink>; Department of Medical Oncology, University Medical Center Groningen, University Groningen, 9713 GZ, Groningen, The Netherlands.<br /><searchLink fieldCode="AU" term="%22Labots+M%22">Labots M</searchLink>; Department of Medical Oncology, Cancer Center Amsterdam, Vrije Universiteit Amsterdam, Amsterdam UMC, 1081 HV, Amsterdam, The Netherlands.<br /><searchLink fieldCode="AU" term="%22Kouwenhoven+MCM%22">Kouwenhoven MCM</searchLink>; Department of Neurology, Cancer Center Amsterdam, Vrije Universiteit Amsterdam, Amsterdam UMC, 1081 HV, Amsterdam, The Netherlands.<br /><searchLink fieldCode="AU" term="%22Sanchez+Aliaga+E%22">Sanchez Aliaga E</searchLink>; Department of Radiology and Nuclear Medicine, Vrije Universiteit Amsterdam, Amsterdam UMC, 1081 HV, Amsterdam, The Netherlands.<br /><searchLink fieldCode="AU" term="%22Enting+RH%22">Enting RH</searchLink>; Department of Neurology, University Medical Center Groningen, University Groningen, 9713 GZ, Groningen, The Netherlands.<br /><searchLink fieldCode="AU" term="%22de+Groot+JC%22">de Groot JC</searchLink>; Department of Radiology, Medical Imaging Center, University Medical Center Groningen, University Groningen, 9713 GZ, Groningen, The Netherlands.<br /><searchLink fieldCode="AU" term="%22Walenkamp+AME%22">Walenkamp AME</searchLink>; Department of Medical Oncology, University Medical Center Groningen, University Groningen, 9713 GZ, Groningen, The Netherlands.<br /><searchLink fieldCode="AU" term="%22van+Linde+ME%22">van Linde ME</searchLink>; Department of Medical Oncology, Cancer Center Amsterdam, Vrije Universiteit Amsterdam, Amsterdam UMC, 1081 HV, Amsterdam, The Netherlands.<br /><searchLink fieldCode="AU" term="%22Verheul+HMW%22">Verheul HMW</searchLink>; Department of Medical Oncology, Research Institute for Medical Innovation, Radboud University Medical Center, 6525 GA, Nijmegen, The Netherlands.; Department of Medical Oncology, Erasmus University Medical Center, Cancer Institute, 3015 GD, Rotterdam, The Netherlands.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101755125%22">Brain communications</searchLink> [Brain Commun] 2024 Jul 30; Vol. 6 (4), pp. fcae241. <i>Date of Electronic Publication: </i>2024 Jul 30 (<i>Print Publication: </i>2024).
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Clinical Trial; Journal Article
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Oxford+University+Press%22">Oxford University Press </searchLink><i>Country of Publication: </i>England <i>NLM ID: </i>101755125 <i>Publication Model: </i>eCollection <i>Cited Medium: </i>Internet <i>ISSN: </i>2632-1297 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2226321297%22">26321297 </searchLink><i>NLM ISO Abbreviation: </i>Brain Commun <i>Subsets: </i>PubMed not MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=39114330
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1093/braincomms/fcae241
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: fcae241
    Titles:
      – TitleFull: The STELLAR trial: a phase II/III randomized trial of high-dose, intermittent sunitinib in patients with recurrent glioblastoma.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Janssen JBE
      – PersonEntity:
          Name:
            NameFull: Brahm CG
      – PersonEntity:
          Name:
            NameFull: Driessen CML
      – PersonEntity:
          Name:
            NameFull: Nuver J
      – PersonEntity:
          Name:
            NameFull: Labots M
      – PersonEntity:
          Name:
            NameFull: Kouwenhoven MCM
      – PersonEntity:
          Name:
            NameFull: Sanchez Aliaga E
      – PersonEntity:
          Name:
            NameFull: Enting RH
      – PersonEntity:
          Name:
            NameFull: de Groot JC
      – PersonEntity:
          Name:
            NameFull: Walenkamp AME
      – PersonEntity:
          Name:
            NameFull: van Linde ME
      – PersonEntity:
          Name:
            NameFull: Verheul HMW
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 30
              M: 07
              Text: 2024 Jul 30
              Type: published
              Y: 2024
          Identifiers:
            – Type: issn-electronic
              Value: 2632-1297
          Numbering:
            – Type: volume
              Value: 6
            – Type: issue
              Value: 4
          Titles:
            – TitleFull: Brain communications
              Type: main
ResultId 1